Abstract | OBJECTIVE: STUDY DESIGN: A multicenter, open-label, nonrandomized clinical trial was conducted on subjects who were 19-29 years of age with clinical symptoms and signs of endometriosis demonstrated by laparoscopy, ultrasonography, magnetic resonance imaging, computed tomography or pelvic examination. For 24 weeks, 34 women received intranasal nafarel, 200 mg twice daily. The main outcome measures were changes in signs and symptoms, lumbar bone mineral density by dual energy X-ray absorptiometry and serum parameters of lipid metabolism. RESULTS: CONCLUSION: Twenty-four-week nafarelin treatment for clinical endometriosis symptoms in women < or = 29 years was safe and effective.
|
Authors | T Kurabayashi, K Takakuwa, K Tanaka |
Journal | The Journal of reproductive medicine
(J Reprod Med)
Vol. 45
Issue 6
Pg. 454-60
(Jun 2000)
ISSN: 0024-7758 [Print] United States |
PMID | 10900577
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cholesterol, HDL
- Cholesterol, LDL
- Hormones
- Lipids
- Triglycerides
- Nafarelin
- Estradiol
|
Topics |
- Absorptiometry, Photon
- Administration, Intranasal
- Adult
- Bone Density
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Endometriosis
(drug therapy)
- Estradiol
(blood)
- Female
- Hormones
(administration & dosage, therapeutic use)
- Humans
- Lipids
(blood)
- Nafarelin
(administration & dosage, therapeutic use)
- Treatment Outcome
- Triglycerides
(blood)
|